Miami Herald Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
FDA Rejects Dynavax's Heplisav
By: MarketMinute.com Stock News
Posted on February 25, 2013 at 12:04 PM EST

The Food and Drug Administration rejected Dynavax Technologies Corp.'s (Nasdaq: DVAX) hepatitis B vaccine Heplisav sending the stock price tumbling 96 cents to $2.01.
Related Stocks:
Dynavax Technologies Corporation
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here